Skip to main content
Top
Published in: Annals of Nuclear Medicine 10/2021

01-10-2021 | Aspiration Pneumonia | Original Article

99mTc-labelled glucosamine in the assessment of systemic sclerosis inflammatory lung disease: a novel inexpensive investigative tool with predictive value.

Authors: H. Englert, BL. Richards, S. Angelides, V. Kumar, D. Spencer, G. Howe, N. Manolios

Published in: Annals of Nuclear Medicine | Issue 10/2021

Login to get access

Abstract

Objective

To evaluate the role of 99mTc-labelled glucosamine [99mTc-ECDG] as a clinical biomarker for the early detection of interstitial lung disease (ILD) in systemic sclerosis (SSc).

Methods

In this prospective pilot study, glucosamine scanning (GS) was performed in 15 SSc patients, with and without ILD. Collected data included patient disease characteristics, autoantibody profile, GS results, high-resolution computerised tomography [HRCT], pulmonary function tests [PFT], and transthoracic echocardiogram [TTE]. Glucosamine results were correlated with patient clinical profile, HRCT, and PFT’s findings.

Results

Lung uptake of 99mTc-ECDG was high in 4 patients, moderate in 3, mild in 5, and normal in 3 with SSc, respectively. Of the patients with high and moderate uptake there was a 100% correlation between 99mTc-ECDG uptake and HRCT showing ILD. Of the 5 patients with mild 99mTc-ECDG uptake, 4 patients had aspiration pneumonia, and 1 had early ILD using HRCT. Of the 3 patients with normal 99mTc-ECDG, 2 had normal HRCTs; the third had severe pulmonary arterial hypertension with minimal HRCT changes of ILD. High and moderate 99mTc-ECDG lung uptake predicted abnormal PFT’s in 100% of cases. In 3 patients, there was less extensive disease depicted on the 99mTc-ECDG scans than on the HRCT. These patients demonstrated a more favourable outcome than would have been expected from the HRCT scans alone. Mild 99mTc-ECDG lung uptake correlated with abnormal PFT’s in 60% of cases. The pattern of 99mTc-ECDG uptake was excellent (100%) at distinguishing metabolically active ILD from aspiration pneumonia. Diffuse uptake was noted in the former and patchy uptake in the latter disease entity.

Conclusion

Increased 99mTc-ECDG uptake in scleroderma lung correlated positively with both structural and functional changes. 99mTc-ECDG is a useful adjunct helping elucidate inflammation secondary to aspiration pneumonia and/or other causes of abnormal PFT’s.
Literature
1.
go back to reference Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis 1972–2002. Ann Rheum Dis. 2007;66(7):940–4.CrossRef Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis 1972–2002. Ann Rheum Dis. 2007;66(7):940–4.CrossRef
2.
go back to reference Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bansel DF, Allanore Y, Muller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15.CrossRef Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bansel DF, Allanore Y, Muller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15.CrossRef
3.
go back to reference Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;229(127):6–19.CrossRef Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;229(127):6–19.CrossRef
4.
go back to reference Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African American race and antibodies to topoisomerase 1 are associated with increased severity of scleroderma lung disease. Chest. 1998;114(3):801–7.CrossRef Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African American race and antibodies to topoisomerase 1 are associated with increased severity of scleroderma lung disease. Chest. 1998;114(3):801–7.CrossRef
5.
go back to reference R Steele M Hudson E Lo M Baron Canadian Scleroderma Research Group 2012 Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis Arthritis Care Res 64 4 519 524 R Steele M Hudson E Lo M Baron Canadian Scleroderma Research Group 2012 Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis Arthritis Care Res 64 4 519 524
6.
go back to reference Morelli S, Barbieri C, Sgreccia A, Ferrante L, Pittoni V, Conti F, Gualdi G, Polettini E, Carlesimo OA, Calvieri S. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 1991;24(1):81–5. Morelli S, Barbieri C, Sgreccia A, Ferrante L, Pittoni V, Conti F, Gualdi G, Polettini E, Carlesimo OA, Calvieri S. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 1991;24(1):81–5.
7.
go back to reference Launay D, Remy-Jardin M, Mihon-Pasturel M, Mastera I, Hachulla E, Lambert M, Delannoy V, Querrel V, Duhamel A. Matran R et al High resolution computerised tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33(9):1789–801.PubMed Launay D, Remy-Jardin M, Mihon-Pasturel M, Mastera I, Hachulla E, Lambert M, Delannoy V, Querrel V, Duhamel A. Matran R et al High resolution computerised tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33(9):1789–801.PubMed
8.
go back to reference Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashon S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP. Scleroderma Lung Study Research Group high resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008;134:358–67.CrossRef Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashon S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP. Scleroderma Lung Study Research Group high resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008;134:358–67.CrossRef
9.
go back to reference D Giuggioli F Lumetti M Colaci P Fallahi A Antonelli C Ferri 2015 Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature Autoimmun Rev 14 11 1072 1078. D Giuggioli F Lumetti M Colaci P Fallahi A Antonelli C Ferri 2015 Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature Autoimmun Rev 14 11 1072 1078.
10.
go back to reference Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Gioconelli R, et al. Low dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16(4):R144.CrossRef Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Gioconelli R, et al. Low dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16(4):R144.CrossRef
11.
go back to reference Fischer A, Brown KK, Du Bois RM, Frankel AK, Cosgrove GP, Fendandez-Perez ER. Huie TJ at al Mycophenylate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–6.CrossRef Fischer A, Brown KK, Du Bois RM, Frankel AK, Cosgrove GP, Fendandez-Perez ER. Huie TJ at al Mycophenylate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–6.CrossRef
12.
go back to reference PM Hassoun 2011 Lung involvement in systemic sclerosis Presse Med 40 1 Pt2 e25 e39 PM Hassoun 2011 Lung involvement in systemic sclerosis Presse Med 40 1 Pt2 e25 e39
13.
go back to reference Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with RA. Clin Nucl Med. 2006 Jul;31(7):386–90.CrossRef Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with RA. Clin Nucl Med. 2006 Jul;31(7):386–90.CrossRef
14.
go back to reference Gupta P, Ponzo F, Kramer EL. Fluorodeoxyglucose (FDG) uptake in pulmonary rheumatoid nodules. Clin Rheumatol. 2005 Aug;24(4):402–5.CrossRef Gupta P, Ponzo F, Kramer EL. Fluorodeoxyglucose (FDG) uptake in pulmonary rheumatoid nodules. Clin Rheumatol. 2005 Aug;24(4):402–5.CrossRef
15.
go back to reference Beckers C, Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, Kaiser MJ, Hustinx R, Foidart J, Malaise MG. Assessment of disease activity in RA with (18)F-FDG PET. J Nucl Med. 2004 Jun;45(6):956–64.PubMed Beckers C, Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, Kaiser MJ, Hustinx R, Foidart J, Malaise MG. Assessment of disease activity in RA with (18)F-FDG PET. J Nucl Med. 2004 Jun;45(6):956–64.PubMed
16.
go back to reference Umekita K, Takajo I, Miyauchi S, et al. (18F) fluorodeoxyglucose positron emission tomography is a useful tool to diagnose the early stage of Takayasu’s arteritis and to evaluate the activity of the disease. Mod Rheumatol. 2006;16(4):243–7.CrossRef Umekita K, Takajo I, Miyauchi S, et al. (18F) fluorodeoxyglucose positron emission tomography is a useful tool to diagnose the early stage of Takayasu’s arteritis and to evaluate the activity of the disease. Mod Rheumatol. 2006;16(4):243–7.CrossRef
17.
go back to reference Walter MA, Melzer RA, Schindler C, et al. The value of (18F) FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):674–81.CrossRef Walter MA, Melzer RA, Schindler C, et al. The value of (18F) FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):674–81.CrossRef
18.
go back to reference Yukihiro M, Yang DJ, Azhdarinia A, Yu D, Kim C. Assessment of tumor growth with 99mTc-EC-Glucosamine. J Nuc Med. 2003;44(Suppl):299P. Yukihiro M, Yang DJ, Azhdarinia A, Yu D, Kim C. Assessment of tumor growth with 99mTc-EC-Glucosamine. J Nuc Med. 2003;44(Suppl):299P.
19.
go back to reference Azhdarinia A, Yang DJ, Yukihiro M. Imaging dosimetry and acute toxicity with 99mTc-EC-deoxyglucose in tumor-bearing animals. J Nuc Med. 2003;45(Suppl):323P. Azhdarinia A, Yang DJ, Yukihiro M. Imaging dosimetry and acute toxicity with 99mTc-EC-deoxyglucose in tumor-bearing animals. J Nuc Med. 2003;45(Suppl):323P.
20.
go back to reference Angelides S, El-Mashaleh M, Anagnostou M, Howe G, Spencer D, Kumar V, Manolios N. The role of 99mTc-labelled glucosamine (99mTc-ECDG) in the evaluation of rheumatic joint disease: a screening experience. Nucl Med Commun. 2014 Jun;35(6):655–65.CrossRef Angelides S, El-Mashaleh M, Anagnostou M, Howe G, Spencer D, Kumar V, Manolios N. The role of 99mTc-labelled glucosamine (99mTc-ECDG) in the evaluation of rheumatic joint disease: a screening experience. Nucl Med Commun. 2014 Jun;35(6):655–65.CrossRef
21.
go back to reference Manolios N, Ali M, Camden B, Eflaki E, Pavic K, Markewycz A, DeCosta R, Angelides S. Evaluating disease activity in patients with ankylosing spondylitis and rheumatoid arthritis using 99mTc-glucosamine. Eur J Rheumatol. 2016 Jun;3(2):65–72.CrossRef Manolios N, Ali M, Camden B, Eflaki E, Pavic K, Markewycz A, DeCosta R, Angelides S. Evaluating disease activity in patients with ankylosing spondylitis and rheumatoid arthritis using 99mTc-glucosamine. Eur J Rheumatol. 2016 Jun;3(2):65–72.CrossRef
22.
go back to reference Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18(10):1520–8.PubMed Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18(10):1520–8.PubMed
23.
go back to reference Yang DJ, Kim CG, Schechter NR, Azhdarinia A, Yu DF, Oh CS, Bryant JL, Won JJ, Kim EE, Podoloff DA. Imaging with 99mTc-GS Targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology. 2003;226(2):465–73.CrossRef Yang DJ, Kim CG, Schechter NR, Azhdarinia A, Yu DF, Oh CS, Bryant JL, Won JJ, Kim EE, Podoloff DA. Imaging with 99mTc-GS Targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology. 2003;226(2):465–73.CrossRef
24.
go back to reference MM Khalil JL Tremoleda TB Bayomy W Gsell 2011 Molecular SPECT Imaging: An Overview Int J Mol Imaging 1 15 MM Khalil JL Tremoleda TB Bayomy W Gsell 2011 Molecular SPECT Imaging: An Overview Int J Mol Imaging 1 15
25.
go back to reference Peelen DM, Zwezerijnen BGJC, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, Voskuyl AE. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology. 2020 Oct;59:1407–15.CrossRef Peelen DM, Zwezerijnen BGJC, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, Voskuyl AE. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology. 2020 Oct;59:1407–15.CrossRef
26.
go back to reference Bellando Randone S, Tartarelli L, Cavigli E, at al. 18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. Annals of the Rheumatic Diseases 2019; 78:577–578. Bellando Randone S, Tartarelli L, Cavigli E, at al. 18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. Annals of the Rheumatic Diseases 2019; 78:577–578.
27.
go back to reference Ledoult E, Morelle M, Soussan M, Mékinian A, Béhal H, Sobanski V, Hachulla E, Huglo D, Le Gouellec N, Remy-Jardin M, Baillet C, Ledoult DL, et al. 18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res Ther. 2021;23:76–87.CrossRef Ledoult E, Morelle M, Soussan M, Mékinian A, Béhal H, Sobanski V, Hachulla E, Huglo D, Le Gouellec N, Remy-Jardin M, Baillet C, Ledoult DL, et al. 18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res Ther. 2021;23:76–87.CrossRef
Metadata
Title
99mTc-labelled glucosamine in the assessment of systemic sclerosis inflammatory lung disease: a novel inexpensive investigative tool with predictive value.
Authors
H. Englert
BL. Richards
S. Angelides
V. Kumar
D. Spencer
G. Howe
N. Manolios
Publication date
01-10-2021
Publisher
Springer Singapore
Published in
Annals of Nuclear Medicine / Issue 10/2021
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-021-01653-0

Other articles of this Issue 10/2021

Annals of Nuclear Medicine 10/2021 Go to the issue